Icotinib Hydrochloride (BPI-2009H) is the hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of EGFR, with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types.
Molecular Weight:
427.88
Purity:
99.89%
CAS Number:
[1204313-51-8]
Formula:
C22H22ClN3O4
Target:
EGFR
T2307
* VAT and and shipping costs not included. Errors and price changes excepted
